A Phase II study to demonstrate the safety and efficacy of CXA-10 in the treatment of focal segmentalGlomerulosclerosis (FSGS).
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2017
At a glance
- Drugs CXA 10 (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Adverse reactions; Therapeutic Use
- 26 Jul 2017 According to Complexa media release, this trial will initiate in early 2018.
- 20 Nov 2015 New trial record
- 12 Nov 2015 According to Complexa media release, this trial will initiate trials 2016.